# A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma

> **NCT05442554** · PHASE4 · COMPLETED · sponsor: **Takeda** · enrollment: 10 (actual)

## Conditions studied

- T-Cell Lymphoma

## Interventions

- **DRUG:** Brentuximab vedotin

## Key facts

- **NCT ID:** NCT05442554
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-28
- **Primary completion:** 2024-08-09
- **Final completion:** 2024-08-09
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05442554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05442554, "A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05442554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*